免疫系统
癌症研究
整合素
癌症
趋化因子
癌细胞
生物
先天免疫系统
细胞粘附
尿激酶受体
细胞
趋化因子受体
癌症免疫疗法
体内
免疫疗法
免疫学
炎症
CXCR4型
转移
TLR7型
医学
树突状细胞
细胞生物学
重编程
受体
癌相关成纤维细胞
T细胞
癌症疫苗
CTL公司*
获得性免疫系统
趋化性
化学
作者
Yanan Tan,Lu Bai,Lifen Zhang,Min Luo,Quan Wan,Yunzhi Liu,Baifeng Zhang,Ziyang Qi,LanQi Gong,Shanshan Li,ZhiTong Bing,Lei Yang,Zhihao Xing,Zuhua Wang,Anne W.M. Lee,Xin‐Yuan Guan
标识
DOI:10.1073/pnas.2619464123
摘要
Despite advances of biomimetic vesicles in cancer therapy, clinical challenges such as biosafety, scalability, and therapeutic efficacy remain significant hurdles. To address these limitations, we reveal the critical tumor-homing motifs of cancer cell membrane vesicles: a synergistic “chemotactic recruitment-adhesion anchoring” cascade effect, especially chemokine axes (e.g., CXCL12/CXCR4) and integrins (e.g., αVβ3). In this study, we identify autologous fibroblasts as an ideal “chassis” cell for engineering biomimetic carriers. Using this platform, we construct multigene-engineered fibroblast-derived nanovesicles (X-Fb-MNVs) coexpressing critical chemokine receptor CXCR4 and adhesion ligand iRGD, as well as PD-1 and CD47 protein, which achieved robust and broad-spectrum tumor targeting across breast, liver, pancreatic, and colon cancer PDX models. Significantly, CD47-modified X-Fb-MNVs reduced hepatic accumulation and phagocytic clearance, thereby minimizing off-target effects in vivo and improving tumor targeting efficiency. By loading diABZI STING agonist into X-Fb-MNVs with overexpressed PD-1, our system activates both T cell and innate immunity, reversing ICB resistance and achieving 83.3% survival with no tumor recurrence and long-term immune surveillance over 90 d, whereas no mice survived with free diABZI treatment. By merging multimodal targeting, immune reprogramming, and scalable production into a single platform, X-Fb-MNVs represent a remarkable biomimetic system with transformative potential for a wide-spectrum cancer immunotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI